FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993588023> ?p ?o ?g. }

• W1993588023 endingPage "1401" @default.
• W1993588023 startingPage "1393" @default.
• W1993588023 abstract "Background: Fluticasone furoate (FF) is a novel enhanced-affinity corticosteroid for the treatment of allergic rhinitis, delivered by a unique side-actuated device. This study was designed to investigate the efficacy and safety of FF nasal spray (FFNS) 110 μg once daily compared with placebo in adults and adolescents (aged ≥12 years) with seasonal allergic rhinitis (SAR) symptoms caused by mountain cedar (Juniperus ashei) pollen.Methods: This was a randomized, double-blind, placebo-controlled, parallel-group, phase III study conducted over a 2-week period (between 10 December 2004 and 19 January 2005) at seven study sites, in Austin, Texas, USA, and San Antonio, Texas, two metropolitan cities in the central Texas Hill Country located approximately 80 miles apart. Adult and adolescent patients (aged ≥12 years) with SAR, who were sensitized to mountain cedar (Juniperus ashei) pollen, were randomized to receive either FFNS 110 μg (n = 152) or placebo (n = 150) once daily. Patients rated the severity of each nasal symptom (rhinorrhea, nasal congestion, nasal itching, and sneezing) and ocular symptom (redness, watery eyes, itching and burning) on a 4-point categorical scale (0 = none, 3 = severe) in a reflective and instantaneous manner. Patients also rated their overall evaluation of response to therapy.Results: FFNS significantly improved the nasal symptoms of SAR compared with placebo. The least square (LS) mean difference in the reflective total nasal symptom score (TNSS) was −0.777 (p = 0.003). A significant reduction in morning pre-dose instantaneous TNSS was also observed compared with placebo (LS mean difference −0.902; p < 0.001). Patients receiving FFNS had significantly greater improvements from baseline in reflective total ocular symptom scores (TOSS) than those receiving placebo (LS mean difference −0.546; p = 0.008). Significant improvements in ocular symptoms with FFNS versus placebo were also observed for morning pre-dose instantaneous TOSS (LS mean difference −0.519; p = 0.009). FFNS had a favorable safety and tolerability profile: fewer adverse events occurred with FFNS (22%) than with placebo (29%), and no serious adverse events were observed.Conclusions: FFNS 110 μg once daily demonstrated efficacy in relieving both the nasal and ocular symptoms of SAR in adult and adolescent patients.Trial registration: ClinicalTrials.gov identifier: NCT00115622." @default.
• W1993588023 created "2016-06-24" @default.
• W1993588023 creator A5016731920 @default.
• W1993588023 creator A5025442187 @default.
• W1993588023 creator A5038184726 @default.
• W1993588023 creator A5041694829 @default.
• W1993588023 creator A5084883536 @default.
• W1993588023 creator A5085161164 @default.
• W1993588023 date "2009-04-28" @default.
• W1993588023 modified "2023-09-25" @default.
• W1993588023 title "Effectiveness of fluticasone furoate 110 μg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen" @default.
• W1993588023 cites W2000739801 @default.
• W1993588023 cites W2001450061 @default.
• W1993588023 cites W2025255009 @default.
• W1993588023 cites W2031208354 @default.
• W1993588023 cites W2033093465 @default.
• W1993588023 cites W2034923714 @default.
• W1993588023 cites W2050077181 @default.
• W1993588023 cites W2050842123 @default.
• W1993588023 cites W2056375655 @default.
• W1993588023 cites W2068715975 @default.
• W1993588023 cites W2073254034 @default.
• W1993588023 cites W2076307982 @default.
• W1993588023 cites W2080515725 @default.
• W1993588023 cites W2134145794 @default.
• W1993588023 cites W2137059404 @default.
• W1993588023 cites W2163304234 @default.
• W1993588023 cites W2164132449 @default.
• W1993588023 cites W72448069 @default.
• W1993588023 doi "https://doi.org/10.1185/03007990902890512" @default.
• W1993588023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19419338" @default.
• W1993588023 hasPublicationYear "2009" @default.
• W1993588023 type Work @default.
• W1993588023 sameAs 1993588023 @default.
• W1993588023 citedByCount "35" @default.
• W1993588023 countsByYear W19935880232012 @default.
• W1993588023 countsByYear W19935880232013 @default.
• W1993588023 countsByYear W19935880232014 @default.
• W1993588023 countsByYear W19935880232015 @default.
• W1993588023 countsByYear W19935880232016 @default.
• W1993588023 countsByYear W19935880232019 @default.
• W1993588023 countsByYear W19935880232020 @default.
• W1993588023 countsByYear W19935880232021 @default.
• W1993588023 countsByYear W19935880232022 @default.
• W1993588023 countsByYear W19935880232023 @default.
• W1993588023 crossrefType "journal-article" @default.
• W1993588023 hasAuthorship W1993588023A5016731920 @default.
• W1993588023 hasAuthorship W1993588023A5025442187 @default.
• W1993588023 hasAuthorship W1993588023A5038184726 @default.
• W1993588023 hasAuthorship W1993588023A5041694829 @default.
• W1993588023 hasAuthorship W1993588023A5084883536 @default.
• W1993588023 hasAuthorship W1993588023A5085161164 @default.
• W1993588023 hasConcept C126322002 @default.
• W1993588023 hasConcept C141071460 @default.
• W1993588023 hasConcept C142724271 @default.
• W1993588023 hasConcept C16005928 @default.
• W1993588023 hasConcept C19720800 @default.
• W1993588023 hasConcept C203014093 @default.
• W1993588023 hasConcept C204787440 @default.
• W1993588023 hasConcept C207480886 @default.
• W1993588023 hasConcept C27081682 @default.
• W1993588023 hasConcept C2776804153 @default.
• W1993588023 hasConcept C2777844070 @default.
• W1993588023 hasConcept C2778311950 @default.
• W1993588023 hasConcept C2779028295 @default.
• W1993588023 hasConcept C2779699568 @default.
• W1993588023 hasConcept C2779923671 @default.
• W1993588023 hasConcept C2780973058 @default.
• W1993588023 hasConcept C2781348165 @default.
• W1993588023 hasConcept C42219234 @default.
• W1993588023 hasConcept C71924100 @default.
• W1993588023 hasConcept C85663871 @default.
• W1993588023 hasConcept C98274493 @default.
• W1993588023 hasConceptScore W1993588023C126322002 @default.
• W1993588023 hasConceptScore W1993588023C141071460 @default.
• W1993588023 hasConceptScore W1993588023C142724271 @default.
• W1993588023 hasConceptScore W1993588023C16005928 @default.
• W1993588023 hasConceptScore W1993588023C19720800 @default.
• W1993588023 hasConceptScore W1993588023C203014093 @default.
• W1993588023 hasConceptScore W1993588023C204787440 @default.
• W1993588023 hasConceptScore W1993588023C207480886 @default.
• W1993588023 hasConceptScore W1993588023C27081682 @default.
• W1993588023 hasConceptScore W1993588023C2776804153 @default.
• W1993588023 hasConceptScore W1993588023C2777844070 @default.
• W1993588023 hasConceptScore W1993588023C2778311950 @default.
• W1993588023 hasConceptScore W1993588023C2779028295 @default.
• W1993588023 hasConceptScore W1993588023C2779699568 @default.
• W1993588023 hasConceptScore W1993588023C2779923671 @default.
• W1993588023 hasConceptScore W1993588023C2780973058 @default.
• W1993588023 hasConceptScore W1993588023C2781348165 @default.
• W1993588023 hasConceptScore W1993588023C42219234 @default.
• W1993588023 hasConceptScore W1993588023C71924100 @default.
• W1993588023 hasConceptScore W1993588023C85663871 @default.
• W1993588023 hasConceptScore W1993588023C98274493 @default.
• W1993588023 hasIssue "6" @default.
• W1993588023 hasLocation W19935880231 @default.
• W1993588023 hasLocation W19935880232 @default.
• W1993588023 hasOpenAccess W1993588023 @default.

• next